| The hypothesis that tumor growth is angiogenesis-dependent has been supported by extensive experimental evidence, and has also been confirmed by genetic methods. The switch to the angiogenic phenotype is a critical point in tumor progression. Before this switch occurs, most tumors are restricted to a microscopic size(1～2mm3). During the period of angiogenesis there are neocapillaries and the growth of tumor becomes faster. Researchers from two leading laboratories of vascular biology demonstrate that approximately 15% of vessels in a human colon carcinoma in mice contain a subpopulation of tumor cells that share space in the vessel wall with endothelial cells and tumor cells in transit to the vascular lumen may reside temporarily in the microvessel wall and occupy up to 4% of the total vascular surface area. Because VEGF is a potent mistosigen and vascular permeabilizing factor, VEGF plays a critical role in both physiological and pathological angiogenesis. Considering that the important status of angiogensis in the tumor prolifration and metastasis had been confirmed, and that the detection methods of VEGF are simple and conventional, many scholars concentrate the study on the biology and expression and regulation and clinical applications of VEGF in the tumor. In order to investigate the expression and regulation of VEGF in tumor tissues, we use immunohistochemistry, sandwith enzyme immunoassay and antisense oligodeoxynucliolide to study the inflencesof lower Hemoglobin and radiation on VEGF expression and the inhibition of antisenseoligodeoxynucleotide to heptic cell carcinoma.Objective ①To detect the relationship between expression of the vascular endothelial growth factor (VEGF) in colorectal carcinoma and Ducks'stage and in association with the expression of p53 protein, a potential suppressor of tumor angiogenesis.② To study whether the serum vascular endothelial growth factor (VEGF) level in patients with tumour could be used as a predictor of diagnosis, recurrence and disease progress. ③To study the influence of lower hemoglobin on the serum VEGF and the increasing mechanism of the serum VEGF in the tumor patients during radiotherapy.The inhibitory action of the antisense oligodeoxynucleotide to the expression of VEGF protein after radiating the liver cancer cell.MethodThe immunohistochemical (IHC) expression of VEGF and p53 was examined in paraffin sections of 77 colorectal carcinomas. Statistical analysis was performed with the χ2 test. Serum levels of VEGF in 30 healthy controls, 85 patients with colorectal cancinomas, 34 case pneumonia and 96 patients with lung cancer were measured using a sandwich enzyme immunoassay (ELISA), and the results were analyzed with respect to several clinical pathologic factors；To view the changes of the serum VEGF in the tumor patients with lower hemoglobin and during radiotherapy and the inhibitory action of the antisense oligodeoxynucleotide to the expression of vascular endothelial growth factor by radiotherapy in a liver cancer cell line.RESULTSHigh VEGF expression rate (49/77,62.3%) were observed in thepatients with colorectal carcinomas and especially in the patients with beyond viscera metastases(4/4,100%). VEGF expression related with Duck's stage (P＜0.001). A significant association was noted between VEGF and p53 expression. Significant difference in the VEGF level was observed between controls and the patients (P <0.001) and between control and patients with Dukes'A stage (P <0.01). Whereas there was no significant difference between healthy control and high differentiation cancers (P = 0.896) in the serum VEGF levels The VEGF levels were significantly associated with Dukes' stages of the patients (P < 0.01). Patients with lymph node metastasis (Dukes C) had higher VEGF levels than those without metastasis (Dukes B, P >0.05). There were significantly differences between patients with recurrence and no-recurrence after surgical resection (P<0.01). Significant difference in the VEGF level was observed betwee...
|
PDF Full Text Request